|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,086 GBX | -1.77% |
|
-3.70% | +14.02% |
| 07-02 | ASTRAZENECA : Jefferies reaffirms its Neutral rating | ZD |
| 07-02 | Deutsche Bank cuts Quilter, ups Polar Capital | AN |
July 1 (Reuters) - AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
The submission was based on positive data from a late-stage trial that showed the drug helped reduce the incidence of COVID-19 in immunocompromised patients.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sonia Cheema)
| 1st Jan change | Capi. | |
|---|---|---|
| +14.02% | 238B | |
| +55.55% | 816B | |
| +42.31% | 634B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +1.64% | 222B | |
| +13.66% | 218B | |
| +7.87% | 167B | |
| -3.33% | 158B |
ASTRAZENECA PLC 
